Our research team has identified potential therapeutic targets for COVID-19


Science and Technology Daily (Reporter Ye Qing correspondent Liu Yuntao Guo Jianwen) March 15, the reporter learned from Guangzhou University of Traditional Chinese Medicine that recently,The team of Zhang Zhongde, vice president of the University and vice President of Guangdong Hospital of Traditional Chinese Medicine (The Second Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine), and The team of Qin Jun, professor of Beijing Proteome Research Center, have discovered potential therapeutic targets for COVID-19. The research results are published in Science China: Life Sciences.This study identified a protein CLYBL that has not yet been included in the common database of bioinformatics annotations, but is highly expressed only in the urine of COVID-19 patients, and speculated that the immunomodulatory metabolite itaconic acid could serve as a potential therapeutic target for COVID-19.After the outbreak of COVID-19, in order to timely early detection and early intervention to block the disease progression of COVID-19 patients, on the basis of the novel Coronavirus (SARS-COV-2) receptor protein ACE2 detected in the urine of healthy people by Qin Jun’s team, Zhang Zhongde and Qin Jun’s team, based on the characteristics of easy urine acquisition and collection,Rapid research on the urine proteome of COVID-19 patients was carried out.”We analyzed the urine proteome and found significant changes in proteins associated with immune and metabolic function in COVID-19 patients.”More surprisingly, a pathway involved in the body’s own antiviral immune response was activated in the urine of COVID-19 patients. Proteins associated with this pathway were significantly overexpressed, suggesting that SARS-COV-2 activates the innate immune response in humans, suggesting that urine can reflect changes in the body of people infected with SARS-CoV-2.”Qin Jun said.By comparing the urine proteome of 86 PATIENTS with COVID-19, 55 patients with common pneumonia, and 176 healthy controls, the team identified a protein CLYBL that was highly expressed only in the urine of COVID-19 patients.CLYBL is A lyase that converts itaconic acid into acetyl-coA.Itaconic acid plays an important role in cell protection such as anti-oxidation and anti-inflammation.The high expression of CLYBL may be a key factor leading to the depletion of chaconic acid, an anti-inflammatory metabolite.Therefore, CLYBL and Itaconic acid may be potential therapeutic targets for COVID-19, while itaconic acid supplementation and CLYBL inhibition may be potential therapeutic approaches for COVID-19. This immunoregulatory therapy is more effective and will not be affected by virus mutations, whether Delta or Omicron.This finding has important implications for future research on COVID-19 drugs.(Science and Technology Daily)

Leave a Reply

Your email address will not be published.